BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 38340290)

  • 21. The "three-in-one" formulation of bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practice.
    Zagari RM; Romiti A; Ierardi E; Gravina AG; Panarese A; Grande G; Savarino E; Maconi G; Stasi E; Eusebi LH; Farinati F; Conigliaro R; Bazzoli F; Romano M
    Helicobacter; 2018 Aug; 23(4):e12502. PubMed ID: 29924430
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Shah S; Hubscher E; Pelletier C; Jacob R; Vinals L; Yadlapati R
    Expert Rev Gastroenterol Hepatol; 2022 Apr; 16(4):341-357. PubMed ID: 35315732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rescue therapy with bismuth quadruple regimen in patients with Helicobacter pylori -resistant strains.
    Fiorini G; Saracino IM; Zullo A; Gatta L; Pavoni M; Vaira D
    Helicobacter; 2017 Dec; 22(6):. PubMed ID: 29094477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies.
    Graham DY; Dore MP; Lu H
    Expert Rev Anti Infect Ther; 2018 Sep; 16(9):679-687. PubMed ID: 30102559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria.
    Hsu PI; Pan CY; Kao JY; Tsay FW; Peng NJ; Kao SS; Wang HM; Tsai TJ; Wu DC; Chen CL; Tsai KW;
    Helicobacter; 2018 Aug; 23(4):e12498. PubMed ID: 29897654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The Efficacy of Bismuth-containing Quadruple Therapy after Moxifloxacin-based Sequential Therapy Failure in Helicobacter pylori Eradication].
    Kwon S; Lee DH; Kang JB; Kim N; Park YS; Shin CM; Yoon H; Choi YJ
    Korean J Gastroenterol; 2018 Apr; 71(4):196-203. PubMed ID: 29684968
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bismuth-based quadruple therapy following H. pylori eradication failures: a multicenter study in clinical practice.
    Zullo A; De Francesco V; Bellesia A; Vassallo R; D'Angelo A; Scaccianoce G; Sacco R; Bresci G; Eramo A; Tanzilli A; Ridola L; Alvaro D; Londoni C; Brambilla G; Manta R; Di Ciaula A; Portincasa P
    J Gastrointestin Liver Dis; 2017 Sep; 26(3):225-229. PubMed ID: 28922433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study).
    Treiber G; Wittig J; Ammon S; Walker S; van Doorn LJ; Klotz U
    Arch Intern Med; 2002 Jan; 162(2):153-60. PubMed ID: 11802748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Third-line and rescue therapy for refractory
    de Moraes Andrade PV; Monteiro YM; Chehter EZ
    World J Gastroenterol; 2023 Jan; 29(2):390-409. PubMed ID: 36687120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Helicobacter pylori-associated diseases].
    Gisbert JP
    Gastroenterol Hepatol; 2015 Sep; 38 Suppl 1():39-48. PubMed ID: 26520195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of insufficient doses of medications on
    Shi X; Wang C; Meng F; Ma S; Xu G; Liu T; Guo X; Li H; Qi X
    Postgrad Med; 2022 Sep; 134(7):668-674. PubMed ID: 35860966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vonoprazan is noninferior to proton pump inhibitors in bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: A propensity score matching analysis.
    Wang J; Li YY; Lin MJ; Liu J; Lin BS; Ding YM; Wan M; Zhang WL; Kong QZ; Wang ST; Mu YJ; Duan M; Han ZX; Zuo XL; Li YQ
    J Dig Dis; 2023 Jan; 24(1):19-27. PubMed ID: 36960538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice.
    Tursi A; Di Mario F; Franceschi M; De Bastiani R; Elisei W; Baldassarre G; Ferronato A; Grillo S; Landi S; Zamparella M; De Polo M; Boscariolo L; Picchio M
    Helicobacter; 2017 Jun; 22(3):. PubMed ID: 28125857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy: repeated quadruple therapy as a third-line therapy.
    Lee SK; Lee SW; Park JY; Kwon BS; Kim SY; Hyun JJ; Kim JH; Jung SW; Koo JS; Yim HJ; Choi JH
    Helicobacter; 2011 Oct; 16(5):410-4. PubMed ID: 21923688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modified sequential therapy vs quadruple therapy as initial therapy in patients with Helicobacter infection.
    Liao XM; Nong GH; Chen MZ; Huang XP; Cong YY; Huang YY; Wu BH; Wei JQ
    World J Gastroenterol; 2015 May; 21(20):6310-6. PubMed ID: 26034367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of triple therapy containing berberine hydrochloride, amoxicillin, and rabeprazole in the eradication of Helicobacter pylori.
    Chen XX; Chen YX; Bi HX; Zhao X; Zhang LF; Liu JY; Shi YQ
    J Dig Dis; 2022 Oct; 23(10):568-576. PubMed ID: 36415112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison Between Sequential Therapy and Modified Bismuth-Included Quadruple Therapy for Helicobacter pylori Eradication in Chinese Patients.
    Yang X; Tan P; Song L; Lu Z
    Am J Ther; 2016; 23(6):e1436-e1441. PubMed ID: 25923229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy of culture-guided versus empirical therapy with high-dose proton pump inhibitor as third-line treatment of Helicobacter pylori infection: A real-world clinical experience.
    Wang JW; Hsu PI; Lin MH; Kao J; Tsay FW; Wu IT; Shie CB; Wu DC
    J Gastroenterol Hepatol; 2022 Oct; 37(10):1928-1934. PubMed ID: 35816187
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of 10-day levofloxacin bismuth-based quadruple therapy and levofloxacin-based triple therapy for Helicobacter pylori.
    Wu TS; Hsu PI; Kuo CH; Hu HM; Wu IC; Wang SSW; Chen YH; Wu DC; Su WW; Kuo FC
    J Dig Dis; 2017 Sep; 18(9):537-542. PubMed ID: 28644575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel and Effective Therapeutic Regimens for
    Hu Y; Zhu Y; Lu NH
    Front Cell Infect Microbiol; 2017; 7():168. PubMed ID: 28529929
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.